Immunohistochemistry Market: Global Industry Analysis and Forecast (2022-2029)

Immunohistochemistry Market was valued at US$ 1.95 Bn. in 2021. Global Immunohistochemistry Market size is expected to grow at a CAGR of 8.2 % through the forecast period.

Immunohistochemistry Market Overview:

Using appropriately labeled antibodies that attach selectively to their target antigens in situ, immunohistochemistry (IHC) integrates anatomical, immunological, and biochemical approaches to scan discrete components in tissues. IHC enables the high-resolution distribution and localization of particular cellular components within cells and within their appropriate histological context to be seen and documented. IHC methodology allows for a variety of ways and combinations, but all of the stages are divided into two categories: sample preparation and sample staining. Immunohistochemistry Market To know about the Research Methodology:-Request Free Sample Report The market is expected to grow significantly through the forecast period amid rising automation and machine learning deployment in immunohistochemistry (IHC), as well as the release of technologically enhanced IHC solutions. The demand for IHC in disease diagnosis has increased significantly as a result of improvements in IHC methods. The market is also growing as a result of the rise in product approvals and the introduction of technologically sophisticated IHC equipment for illness diagnostics.

Immunohistochemistry Market Dynamics:

1. The increasing geriatric population and high prevalence of chronic and infectious diseases: The aging population will have a significant impact on the growth of the IHC market in both developed and developing regions. The prevalence of age-related disorders is expected to surge considerably with the geriatric population's rapid growth. Other wealthy nations have sizable and growing senior populations as well. The chance of getting diseases rises proportionately with age. Therefore, it is expected that the prevalence of various diseases will rise significantly as the geriatric population grows. This is thought to be a major driver driving the IHC market for diagnostic applications. 2. New product launches in the market: Market development will be supported by key market leaders focusing more on technological developments in accordance with current needs. In the upcoming years, the market is expected to grow due to the introduction of new products in the immunohistochemistry sector to address the problems mentioned before. The markets leading players are developing cutting-edge technologies that are expected to fuel market growth. For instance, Biocare Medical announced the release of seven novel IVD IHC antibody markers in February 2020 for use in diagnostics and other research applications. The introduction of these clinical diagnostic markers might aid the immuno-oncology field in advancing early medication development for the treatment of cancer. 3. Growing need of Immunohistochemistry (IHC) for drug development: In the upcoming years, the market is expected to grow due to the rising frequency of chronic disorders. The market will grow and capture the most share in the near future due to the increase in patients with cancer, infectious diseases, and cardiovascular disorders where immunohistochemistry is utilized for diagnosis. The alarming rate at which infectious diseases are spreading is a challenge for medical professionals in the development of drugs for such unidentified diseases, and the rise in demand for treatments for such diseases will drive the market to a booming pace in the near future. Obesity rates have been rising quickly in both rich and emerging nations. The increase in the number of obese people is largely due to factors like unhealthy lifestyles and sedentary habits. A round 42% of the population, are expected to be obese. When compared to younger adults, middle-aged adults (44.7%) had a significantly higher frequency of obesity (38.7%). Healthcare costs have increased as a result of the rise in the number of obese people. 4. Increasing healthcare expenditure: Due to rising healthcare spending in developed nations and improving healthcare infrastructure, the biotechnology market is expected to have considerable growth through the forecast period. The market is expected to be driven by a rise in government financing for clinical research including in vitro molecular diagnostics, as these studies are essential to the creation of new products. Significant market growth has been fueled by rising investments in well-known biotech and biopharma businesses. Compared to the United States, Chinese investors are increasingly concentrating on funding European biotech firms. Medication development, production, and distribution are all handled by the pharmaceutical sector. In the last 20 years, the market has grown significantly, and in 2021, total pharma revenues reached USD 1.42 trillion. It is growing with a CAGR of 11.5%. Immunohistochemistry Market Immunohistochemistry Market Restraints: The immunohistochemistry market's growth is being limited by the lack of specificity in techniques and expensive setup costs. The absence of IHC techniques needed for the diagnosis of several chronic diseases poses a hurdle to the market. A considerable burden of high setup costs for automated Immunohistochemistry devices in the diagnostic labs of emerging nations is one of the other obstacles preventing market growth. Over the course of the assessment period, it has stifled market growth. However, it is expected that the healthcare market will undergo a profound transformation and enter a phase of market growth. Immunohistochemistry Market Opportunities: 1. Growing demand for personalized medicine: The usage of personalized medicine is expected to grow in the future due to its extraordinary efficacy in treating non-small-cell lung cancer patients. This method of choosing a course of treatment is backed by immunohistochemistry procedures, which carry out the most thorough and precise histological subtyping of malignancies (supported by predictive immunohistochemistry and the assessment of relevant biomarkers). A beneficial substitute or addition to molecular testing is the increased accessibility of immunohistochemical assays that identify mutant proteins, such as BRAF V600E and IDH1 R132H. These methods are useful new instruments in the treatment of cancer in the current era since they are highly reproducible, involve a manageable level of technical and interpretive complexity, and are substantially less expensive. Immunohistochemistry Market Challenges: 1. lack of qualified professionals: Because cancer is becoming more common, there is a large increase in the demand for pathology services for clinical applications. Most of the examinations carried out on cancer patients use histopathology technology. However, these laboratories are severely short on trained personnel. A tiny number of histopathologists are being trained, and many histopathologists have reached retirement age. However, with a limited staff, laboratories are under pressure to process a growing number of specimens.

Immunohistochemistry Market Segment Analysis:

Based on Product, the Immunohistochemistry Market is segmented into Antibodies, Equipment, Reagents, and Kits. Due to the crucial role that antibodies play in illness diagnosis and medication testing, the antibodies segment dominated the market in 2021 and accounted for more than 42% share. In terms of usage rate, monoclonal antibodies, and related products—such as Fc-fusion, antibody fragments, and antibody-drug conjugates—have taken the lead. The antibodies are used in a variety of fields, including neuropathology, hematopathology, and pathology. Through the forecast period, the kits category is expected to grow at the quickest CAGR. The selection process for the use of an acceptable combination of antibodies and stains against a tissue sample is eliminated when using kits, which significantly decreases the amount of work required during the IHC procedure. This market is expected to be driven by the products' compact design and user-friendliness. Immunohistochemistry Market Based on the End-User, the Immunohistochemistry Market is segmented into Hospitals & Diagnostic Laboratories, Academic & Research Institutes. Revenues from the Hospitals & Diagnostic Laboratories category, which are dominating the market share, are expected to grow rapidly at a CAGR of 8.4% through the forecast period due to the increasing use of diagnostic instruments. The hospital and diagnostic lab end-user sectors account for more than 60% of the total revenue. This growth is related to the large number of IHC tests performed in medical facilities. Furthermore, the need for hospitals with cutting-edge facilities has grown because of the healthcare sector's ongoing changes. In consequence, it is expected that this will increase this segment's revenue flow.

Immunohistochemistry Market Regional Insights:

The North America region dominated the market with a 39 % share in 2021. The North America region is expected to witness significant growth at a CAGR of 8.4% through the forecast period. The presence of significant market participants, the ease with which IHC solutions are accessible, the increased use of technologically advanced IHC instruments, and the arrival of newer IHC solutions are important factors influencing the growth of the regional market. U.S. is the fastest growing country in the North America region growing with a CAGR at 8.5% through the forecast period. Asia Pacific region is the fastest-growing region, and it is expected to grow at a CAGR of around 8.9% through the forecast period. The multinational players' increased geographic presence in the Asian markets is mostly too accountable for this. Additionally, a huge patient base in nations like China and India offers a high number of clinical subjects for IHC R&D tests, which boosts income. Japan, South Korea, and India are the leading countries with the highest CAGR the in Asia Pacific region. They are expected to grow at a CAGR of 10.8%, 9.5%, and 8.6% respectively. The objective of the report is to present a comprehensive analysis of the global Immunohistochemistry Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Immunohistochemistry Market dynamic, structure by analyzing the market segments and projecting the Immunohistochemistry Market size. Clear representation of competitive analysis of key players by Product type, price, financial position, product portfolio, growth strategies, and regional presence in the Immunohistochemistry Market make the report investor’s guide.

Immunohistochemistry Market Scope: Inquire before buying

Global Immunohistochemistry Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US$ 1.95 Bn.
Forecast Period 2022 to 2029 CAGR: 8.2% Market Size in 2029: US$ 3.66 Bn.
Segments Covered: by Product • Antibodies • Equipment • Reagents • Kits
by Application • Diagnostics o Cancer o Infectious Diseases o Cardiovascular Diseases o Autoimmune Diseases o Diabetes Mellitus o Nephrological Diseases • Drug testing
by End-User • Hospitals & Diagnostic Laboratories • Academic & Research Institutes • Other

Immunohistochemistry Market by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Immunohistochemistry Market Key Players

F. Hoffman-La Roche AG (Switzerland) • Danaher Corporation (US) • Agilent Technologies, Inc. (US) • Merck KGaA (Germany) • Bio-Rad Laboratories, Inc. (US) • Bio-Techne Corporation (US) • Abcam plc (UK) • Becton Dickinson and Company (US) • PerkinElmer, Inc. (US) • Takara Bio, Inc. (Japan) • Thermo Fisher Scientific, Inc. (US) • PHC Holdings Corporation (Japan) • Cell Signaling Technology, Inc. (US) • Bio SB, Inc. (US) • Miltenyi Biotec (Germany) • CANDOR Bioscience GmbH (Germany) • Sakura Finetek Japan Co., Ltd. (Japan) • Eagle Biosciences, Inc. (US) • Biocare Medical, LLC (US) Frequently Asked Questions: 1] What segments are covered in the Global Immunohistochemistry Market report? Ans. The segments covered in the Immunohistochemistry Market report are based on Product, Application and End User. 2] Which region is expected to hold the highest share in the Global Immunohistochemistry Market? Ans. The North America region is expected to hold the highest share in the Immunohistochemistry Market. 3] What is the market size of the Global Immunohistochemistry Market by 2029? Ans. The market size of the Immunohistochemistry Market by 2029 is expected to reach US$ 3.66 Bn. 4] What is the forecast period for the Global Immunohistochemistry Market? Ans. The forecast period for the Immunohistochemistry Market is 2022-2029. 5] What was the market size of the Global Immunohistochemistry Market in 2021? Ans. The market size of the Immunohistochemistry Market in 2021 was valued at US$ 1.95 Bn.
1. Global Immunohistochemistry Market Size: Research Methodology 2. Global Immunohistochemistry Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Immunohistochemistry Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Immunohistochemistry Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Immunohistochemistry Market Size Segmentation 4.1. Global Immunohistochemistry Market Size, by Product (2021-2029) • Antibodies • Equipment • Reagents • Kits 4.2. Global Immunohistochemistry Market Size, by Application (2021-2029) • Diagnostics o Cancer o Infectious Diseases o Cardiovascular Diseases o Autoimmune Diseases o Diabetes Mellitus o Nephrological Diseases • Drug testing 4.3. Global Immunohistochemistry Market Size, by End User (2021-2029) • Hospitals & Diagnostic Laboratories • Academic & Research Institutes • Other 5. North America Immunohistochemistry Market (2021-2029) 5.1. North America Immunohistochemistry Market Size, by Product (2021-2029) • Antibodies • Equipment • Reagents • Kits 5.2. North America Immunohistochemistry Market Size, by Application (2021-2029) • Diagnostics o Cancer o Infectious Diseases o Cardiovascular Diseases o Autoimmune Diseases o Diabetes Mellitus o Nephrological Diseases • Drug testing 5.3. North America Immunohistochemistry Market Size, by End User (2021-2029) • Hospitals & Diagnostic Laboratories • Academic & Research Institutes • Other 5.4. North America Immunohistochemistry Market, by Country (2021-2029) • United States • Canada • Mexico 6. European Immunohistochemistry Market (2021-2029) 6.1. European Immunohistochemistry Market, by Product (2021-2029) 6.2. European Immunohistochemistry Market, by Application (2021-2029) 6.3. European Immunohistochemistry Market, by End User (2021-2029) 6.4. European Immunohistochemistry Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Immunohistochemistry Market (2021-2029) 7.1. Asia Pacific Immunohistochemistry Market, by Product (2021-2029) 7.2. Asia Pacific Immunohistochemistry Market, by Application (2021-2029) 7.3. Asia Pacific Immunohistochemistry Market, by End User (2021-2029) 7.4. Asia Pacific Immunohistochemistry Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Immunohistochemistry Market (2021-2029) 8.1. Middle East and Africa Immunohistochemistry Market, by Product (2021-2029) 8.2. Middle East and Africa Immunohistochemistry Market, by Application (2021-2029) 8.3. Middle East and Africa Immunohistochemistry Market, by End User (2021-2029) 8.4. Middle East and Africa Immunohistochemistry Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Immunohistochemistry Market (2021-2029) 9.1. South America Immunohistochemistry Market, by Product (2021-2029) 9.2. South America Immunohistochemistry Market, by Application (2021-2029) 9.3. South America Immunohistochemistry Market, by End User (2021-2029) 9.4. South America Immunohistochemistry Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Becton Dickinson and Company (US) 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. F. Hoffman-La Roche AG (Switzerland) 10.3. Danaher Corporation (US) 10.4. Agilent Technologies, Inc. (US) 10.5. Merck KGaA (Germany) 10.6. Bio-Rad Laboratories, Inc. (US) 10.7. Bio-Techne Corporation (US) 10.8. Abcam plc (UK) 10.9. PerkinElmer, Inc. (US) 10.10. Takara Bio, Inc. (Japan) 10.11. Thermo Fisher Scientific, Inc. (US) 10.12. PHC Holdings Corporation (Japan) 10.13. Cell Signaling Technology, Inc. (US) 10.14. Bio SB, Inc. (US) 10.15. Miltenyi Biotec (Germany) 10.16. CANDOR Bioscience GmbH (Germany) 10.17. Sakura Finetek Japan Co., Ltd. (Japan) 10.18. Eagle Biosciences, Inc. (US) 10.19. Biocare Medical, LLC (US)
  • INQUIRE BEFORE BUYING